Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

Nature Genetics

Volumn 46, Issue 2, 2014, Pages 161-165

  Brastianos, Priscilla K ^a,d   Taylor Weiner, Amaro ^d   Manley, Peter E ^c   Jones, Robert T ^c   Dias Santagata, Dora ^a,b   Thorner, Aaron R ^c   Lawrence, Michael S ^d   Rodriguez, Fausto J ^e   Bernardo, Lindsay A ^a   Schubert, Laura ^c   Sunkavalli, Ashwini ^c   Shillingford, Nick ^f   Calicchio, Monica L ^f   Lidov, Hart G W ^b,f,g   Taha, Hala ^h   Martinez Lage, Maria ⁱ   Santi, Mariarita ^j   Storm, Phillip B ^i,j   Lee, John Y K ⁱ   Palmer, James N ⁱ   Adappa, Nithin D ⁱ   Scott, R Michael ^b,f   Dunn, Ian F ^b,g   Laws, Edward R ^b,g   Stewart, Chip ^d   Ligon, Keith L ^b,c,f,g   Hoang, Mai P ^a,b   Van Hummelen, Paul ^b,c   Hahn, William C ^b,c,d   Louis, David N ^a,b   Resnick, Adam C ^i,j   Kieran, Mark W ^b,c,f   Getz, Gad ^a,b,d   Santagata, Sandro ^b,c,f,g   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h CHILDREN S CANCER HOSPITAL   (Egypt)

ⁱ HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ALLELE; ARTICLE; BRAF GENE; CELL DIFFERENTIATION; CELL DIVISION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CRANIOPHARYNGIOMA; CTNNB1 GENE; DNA SEQUENCE; EPIGENETICS; EXOME; GENE; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SOMATIC MUTATION; TRANSCRIPTION REGULATION;

BASE SEQUENCE; BAYES THEOREM; BETA CATENIN; CRANIOPHARYNGIOMA; EXOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA;

EID: 84895831760     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2868     Document Type: Article

References (50)

1. Louis, D.N., Ohgaki, H., Wiestler, O.D. & Cavenee, W.K. WHO Classification of Tumours of the Central Nervous System 238-240 (International Agency for Research on Cancer, 2007
2. Crotty, T.B. et al. Papillary craniopharyngioma: A clinicopathological study of 48 cases. J. Neurosurg. 83, 206-214 (1995
3. Duff, J. et al. Long-Term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46, 291-302, discussion 302-305 (2000
4. Weiner, H.L. et al. Craniopharyngiomas: A clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35, 1001-1010, discussion 1010-1011 (1994
5. Dolecek, T.A., Propp, J.M., Stroup, N.E. & Kruchko, C. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol. 14 (suppl. 5), v1-v49 (2012
6. Liubinas, S.V., Munshey, A.S. & Kaye, A.H. Management of recurrent craniopharyngioma. J. Clin. Neurosci. 18, 451-457 (2011
7. Manley, P.E. et al. Sleep dysfunction in long term survivors of craniopharyngioma. J. Neurooncol. 108, 543-549 (2012
8. Barkhoudarian, G. & Laws, E.R. Craniopharyngioma: History. Pituitary 16, 1-8 (2013
9. Cushing, H. Intracranial tumors: Notes upon a series of two thousand cases with surgical mortality percentages pertaining thereto. JAMA 100, 284 (1932
10. Buslei, R. et al. Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol. 109, 589-597 (2005
11. Kato, K. et al. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma. J. Pathol. 203, 814-821 (2004
12. Sekine, S. et al. Craniopharyngiomas of adamantinomatous type harbor β-catenin gene mutations. Am. J. Pathol. 161, 1997-2001 (2002
13. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013
14. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
15. Brastianos, P.K. et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285-289 (2013
16. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004
17. Stanley, F.K., Moore, S. & Goodarzi, A.A. CHD chromatin remodelling enzymes and the DNA damage response. Mutat. Res. 750, 31-44 (2013
18. Laczmanska, I. & Sasiadek, M.M. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim. Pol. 58, 467-470 (2011
19. Jones, D.T. et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28, 2119-2123 (2009
20. Tian, Y. et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J. Mol. Diagn. 13, 669-677 (2011
21. Capper, D. et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 122, 11-19 (2011
22. Anastas, J.N. & Moon, R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013
23. Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151-1161 (2013
24. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
25. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010
26. Ribas, A. & Flaherty, K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426-433 (2011
27. Sosman, J.A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012
28. Chamberlain, M.C. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: A retrospective case series. J. Neurooncol. 114, 237-240 (2013
29. Rush, S., Foreman, N. & Liu, A. Brainstem ganglioglioma successfully treated with vemurafenib. J. Clin. Oncol. 31, e159-e160 (2013
30. Ascierto, P.A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31, 3205-3211 (2013
31. Sievert, A.J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl. Acad. Sci. USA 110, 5957-5962 (2013
32. Dietrich, S. et al. BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040 (2012
33. Dias-Santagata, D. et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 6, e17948 (2011
34. Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397-405 (2011
35. MacConaill, L.E. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009
36. Demichelis, F. et al. SNP panel identification assay (SPIA): A genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446-2456 (2008
37. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009
38. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011
39. McKenna, A. et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010
40. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011
41. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011
42. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879-3884 (2012
43. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011
44. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012
45. Rickert, C.H. & Paulus, W. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas. J. Neurol. Neurosurg. Psychiatry 74, 260-261 (2003
46. Yoshimoto, M. et al. Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literature. J. Neurosurg. 101, 85-90 (2004
47. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013
48. Thomas, R.K. et al. High-Throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007
49. Corcoran, R.B. et al. BRAF gene amplification can promote acquired resistance to MEKinhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010
50. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146-158 (2010.